Big Pharmas are almost all very large listed corporate entities that have to balance financial market requirements for quarterly earnings growth with the realities of scientific uncertainty.

Typical Big Pharma Profile R&D spend of €500m-€6,000 million per year. Publicly listed. Grown by a series of acquisitions and organic growth. Cost-cutting, especially sales force and R&D. Goal is to satisfy analyst / investor requirements for value creation and steady EBIT growth.

Common Challenges Patent expiries coupled with inadequate and/or stagnating pipelines. Highly complex and cumbersome processes and business models leading to diseconomies of scale, particularly in R&D. Poor return-on-investment due to heavy investments in crowded markets with products that are marginally differentiated. Expensive acquisitions that are not followed through by merger synergies.

NovaSecta Engagement Set up R&D collaborations between Big Pharma and small to mid-sized companies. Find projects from MidPharmas and/or start-up biotechs to fill gaps in Big Pharma pipelines. Build nimble and dynamic organisational units that have the positive characteristics of small or mid-sized companies.